Teva Pharmaceutical Industries (TEVA) Change in Cash (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Change in Cash for 18 consecutive years, with -$86.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Cash fell 118.53% year-over-year to -$86.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 1656.25% YoY), and the FY2025 full-year result was $256.0 million, up 245.95% from the prior year.
• Change in Cash slipped to -$86.0 million in Q2 2026 per TEVA's latest filing, from $185.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $1.4 billion in Q4 2025 and bottomed at -$1.6 billion in Q1 2025.
• Historically, Change in Cash has averaged $81.0 million across 5 years, with a median of $47.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Cash slumped 1365.38% in 2023, then soared 7616.67% in 2025.
• Over 5 years, Change in Cash stood at $576.0 million in 2022, then jumped by 69.62% to $977.0 million in 2023, then slumped by 101.84% to -$18.0 million in 2024, then jumped by 7616.67% to $1.4 billion in 2025, then plunged by 106.36% to -$86.0 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$86.0 million, $185.0 million, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.